Acumen Pharmaceuticals, INC 10-Q quarterly reports

Acumen Pharmaceuticals reported a net loss of $32.7 million for Q2 2026 and highlighted substantial doubt about its ability to continue as a going concern, despite advancing its Alzheimer's disease drug candidates.

Acumen Pharmaceuticals reported a reduced net loss and increased cash reserves in Q1 2026, driven by a private placement, while advancing its Alzheimer's drug candidates.

Acumen Pharmaceuticals reported a widened net loss in Q3 2025, driven by increased R&D for its Alzheimer's drug sabirnetug, with existing capital projected to fund operations into early 2027.

Acumen Pharmaceuticals reported a significant increase in net loss for Q2 2025 driven by higher R&D expenses for its Alzheimer's drug candidate, sabirnetug, while announcing a new strategic collaboration.

Acumen Pharmaceuticals announces its Q1 2025 financial results, showcasing increased R&D spending as it advances its Alzheimer's disease drug candidate, sabirnetug, through clinical trials.

Acumen Pharmaceuticals' Q3 2024 report reveals a significant increase in research and development expenses due to the advancement of their Phase 2 ALTITUDE-AD clinical trial for sabirnetug.

Acumen Pharmaceuticals reported a net loss of $35.4 million for the first half of 2024, while advancing its Alzheimer's drug candidate, sabirnetug, into Phase 2 clinical trials.

Acumen Pharmaceuticals reported a net loss of $14.9 million for the first quarter of 2024, with a focus on advancing their Alzheimer's drug candidate, sabirnetug.